COMMUNIQUÉS West-GlobeNewswire

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
29/06/2026
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy [...]
TerrAscend Files Preliminary Proxy Statement for Special Meeting of Shareholders in Preparation for Uplisting to US Exchange
29/06/2026
TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the “Company”) (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis operator, today announced that it has filed a preliminary proxy statement (the “ [...]
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
29/06/2026
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage [...]
Tria Federal Earns Three Positions on NASA SEWP VI Government-Wide IT Contract
29/06/2026
Awards position Tria and its joint ventures to serve federal health and public safety agencies across the full spectrum of IT and enterprise technology needs ARLINGTON, Va., June 29, 2026 (GLOBE NEWSWIRE) -- Tria [...]
SoldierStrong Donates Life-Changing ExoSym® Device to Marine Corps Veteran and Former Police Officer
29/06/2026
STAMFORD, Conn., June 29, 2026 (GLOBE NEWSWIRE) -- SoldierStrong, a national 501(c)(3) nonprofit dedicated to providing revolutionary medical technology to America's veterans, today announced the donation of an ExoSym® [...]
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
29/06/2026
GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic [...]
Achieve Life Sciences Joins Russell 2000® Index
29/06/2026
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global [...]
Acentra Health Executives Meghan Harris and Verlon Johnson Recognized on Becker’s Healthcare’s 2026 Women in Health IT to Know List
29/06/2026
National recognition underscores Acentra Health leaders' demonstrated impact in advancing healthcare technology, innovation, and improved outcomes across the healthcare ecosystem MCLEAN, Va., June 29, 2026 (GLOBE [...]
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
29/06/2026
SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”) Fast Track is designed to expedite the development/review of new drugs [...]
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
29/06/2026
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant [...]
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
29/06/2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
29/06/2026
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 Advancing a [...]
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
29/06/2026
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
29/06/2026
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced [...]
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
29/06/2026
FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp increased and [...]
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
29/06/2026
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]
Zymeworks to Acquire Theravance Biopharma, Inc.
29/06/2026
Acquisition adds YUPELRI ® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma [...]
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
29/06/2026
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD ~83.5% of [...]
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
29/06/2026
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]

Pages